The Motley Fool shared their current biotech positions. They are holding and recommending Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals. One of their writers, Keith Speights, also has a personal position in Vertex.